A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry

Neurofilament proteins (Nf) are a biomarker of disease progression in amyotrophic lateral sclerosis (ALS). This study investigated whether there are major differences in expression from in vivo measurements of neurofilament isoforms, from the light chain, NfL (68 kDa), compared with larger proteins,...

Full description

Saved in:
Bibliographic Details
Published inJournal of neurochemistry Vol. 146; no. 5; pp. 631 - 641
Main Authors Zucchi, Elisabetta, Lu, Ching‐Hua, Cho, Yunju, Chang, Rakwoo, Adiutori, Rocco, Zubiri, Irene, Ceroni, Mauro, Cereda, Cristina, Pansarasa, Orietta, Greensmith, Linda, Malaspina, Andrea, Petzold, Axel
Format Journal Article
LanguageEnglish
Published England Blackwell Publishing Ltd 01.09.2018
John Wiley and Sons Inc
Subjects
Online AccessGet full text
ISSN0022-3042
1471-4159
1471-4159
DOI10.1111/jnc.14542

Cover

Loading…
Abstract Neurofilament proteins (Nf) are a biomarker of disease progression in amyotrophic lateral sclerosis (ALS). This study investigated whether there are major differences in expression from in vivo measurements of neurofilament isoforms, from the light chain, NfL (68 kDa), compared with larger proteins, the medium chain (NfM, 150 kDa) and the heavy (NfH, 200‐210 kDa) chains in ALS patients and healthy controls. New immunological methods were combined with Nf subunit stoichiometry calculations and Monte Carlo simulations of a coarse‐grained Nf brush model. Based on a physiological Nf subunit stoichiometry of 7 : 3 : 2 (NfL:NfM:NfH), we found an ‘adaptive’ Nf subunit stoichiometry of 24 : 2.4 : 1.6 in ALS. Adaptive Nf stoichiometry preserved NfL gyration radius in the Nf brush model. The energy and time requirements for Nf translation were 56 ± 27k ATP (5.6 h) in control subjects compared to 123 ± 102k (12.3 h) in ALS with ‘adaptive’ (24:2.4:1.6) Nf stoichiometry (not significant) and increased significantly to 355 ± 330k (35.5 h) with ‘luxury’ (7:3:2) Nf subunit stoichiometry (p < 0.0001 for each comparison). Longitudinal disease progression‐related energy consumption was highest with a ‘luxury’ (7:3:2) Nf stoichiometry. Therefore, an energy and time‐saving option for motor neurons is to shift protein expression from larger to smaller (cheaper) subunits, at little or no costs on a protein structural level, to compensate for increased energy demands. This study describes a novel concept, adaptive protein stoichiometry, which provides neurons with an efficient strategy to slow neurodegeneration. The data supporting this conclusion come from protein concentrations measured in patients suffering from a rapid neurodegenerative condition, amyotrophic lateral sclerosis (synonymous motor neuron disease, Lou Gehrig disease). Extrapolation to a much boarder disease spectrum is conceivable as ‘adaptive protein stoichiometry’ is based on the fundamental principle of ATP and time requirements for transcription. The results of present data on the neurofilament triplet protein should be applicable to other heteropolymers and offer a new conceptional framework for developing antisense therapies.
AbstractList Neurofilament proteins (Nf) are a biomarker of disease progression in amyotrophic lateral sclerosis (ALS). This study investigated whether there are major differences in expression from in vivo measurements of neurofilament isoforms, from the light chain, NfL (68 kDa), compared with larger proteins, the medium chain (NfM, 150 kDa) and the heavy (NfH, 200‐210 kDa) chains in ALS patients and healthy controls. New immunological methods were combined with Nf subunit stoichiometry calculations and Monte Carlo simulations of a coarse‐grained Nf brush model. Based on a physiological Nf subunit stoichiometry of 7 : 3 : 2 (NfL:NfM:NfH), we found an ‘adaptive’ Nf subunit stoichiometry of 24 : 2.4 : 1.6 in ALS. Adaptive Nf stoichiometry preserved NfL gyration radius in the Nf brush model. The energy and time requirements for Nf translation were 56 ± 27k ATP (5.6 h) in control subjects compared to 123 ± 102k (12.3 h) in ALS with ‘adaptive’ (24:2.4:1.6) Nf stoichiometry (not significant) and increased significantly to 355 ± 330k (35.5 h) with ‘luxury’ (7:3:2) Nf subunit stoichiometry (p < 0.0001 for each comparison). Longitudinal disease progression‐related energy consumption was highest with a ‘luxury’ (7:3:2) Nf stoichiometry. Therefore, an energy and time‐saving option for motor neurons is to shift protein expression from larger to smaller (cheaper) subunits, at little or no costs on a protein structural level, to compensate for increased energy demands.
Neurofilament proteins (Nf) are a biomarker of disease progression in amyotrophic lateral sclerosis (ALS). This study investigated whether there are major differences in expression from in vivo measurements of neurofilament isoforms, from the light chain, NfL (68 kDa), compared with larger proteins, the medium chain (NfM, 150 kDa) and the heavy (NfH, 200-210 kDa) chains in ALS patients and healthy controls. New immunological methods were combined with Nf subunit stoichiometry calculations and Monte Carlo simulations of a coarse-grained Nf brush model. Based on a physiological Nf subunit stoichiometry of 7 : 3 : 2 (NfL:NfM:NfH), we found an 'adaptive' Nf subunit stoichiometry of 24 : 2.4 : 1.6 in ALS. Adaptive Nf stoichiometry preserved NfL gyration radius in the Nf brush model. The energy and time requirements for Nf translation were 56 ± 27k ATP (5.6 h) in control subjects compared to 123 ± 102k (12.3 h) in ALS with 'adaptive' (24:2.4:1.6) Nf stoichiometry (not significant) and increased significantly to 355 ± 330k (35.5 h) with 'luxury' (7:3:2) Nf subunit stoichiometry (p < 0.0001 for each comparison). Longitudinal disease progression-related energy consumption was highest with a 'luxury' (7:3:2) Nf stoichiometry. Therefore, an energy and time-saving option for motor neurons is to shift protein expression from larger to smaller (cheaper) subunits, at little or no costs on a protein structural level, to compensate for increased energy demands.
Neurofilament proteins (Nf) are a biomarker of disease progression in amyotrophic lateral sclerosis (ALS). This study investigated whether there are major differences in expression from in vivo measurements of neurofilament isoforms, from the light chain, NfL (68 kDa), compared with larger proteins, the medium chain (NfM, 150 kDa) and the heavy (NfH, 200-210 kDa) chains in ALS patients and healthy controls. New immunological methods were combined with Nf subunit stoichiometry calculations and Monte Carlo simulations of a coarse-grained Nf brush model. Based on a physiological Nf subunit stoichiometry of 7 : 3 : 2 (NfL:NfM:NfH), we found an 'adaptive' Nf subunit stoichiometry of 24 : 2.4 : 1.6 in ALS. Adaptive Nf stoichiometry preserved NfL gyration radius in the Nf brush model. The energy and time requirements for Nf translation were 56 ± 27k ATP (5.6 h) in control subjects compared to 123 ± 102k (12.3 h) in ALS with 'adaptive' (24:2.4:1.6) Nf stoichiometry (not significant) and increased significantly to 355 ± 330k (35.5 h) with 'luxury' (7:3:2) Nf subunit stoichiometry (p < 0.0001 for each comparison). Longitudinal disease progression-related energy consumption was highest with a 'luxury' (7:3:2) Nf stoichiometry. Therefore, an energy and time-saving option for motor neurons is to shift protein expression from larger to smaller (cheaper) subunits, at little or no costs on a protein structural level, to compensate for increased energy demands.Neurofilament proteins (Nf) are a biomarker of disease progression in amyotrophic lateral sclerosis (ALS). This study investigated whether there are major differences in expression from in vivo measurements of neurofilament isoforms, from the light chain, NfL (68 kDa), compared with larger proteins, the medium chain (NfM, 150 kDa) and the heavy (NfH, 200-210 kDa) chains in ALS patients and healthy controls. New immunological methods were combined with Nf subunit stoichiometry calculations and Monte Carlo simulations of a coarse-grained Nf brush model. Based on a physiological Nf subunit stoichiometry of 7 : 3 : 2 (NfL:NfM:NfH), we found an 'adaptive' Nf subunit stoichiometry of 24 : 2.4 : 1.6 in ALS. Adaptive Nf stoichiometry preserved NfL gyration radius in the Nf brush model. The energy and time requirements for Nf translation were 56 ± 27k ATP (5.6 h) in control subjects compared to 123 ± 102k (12.3 h) in ALS with 'adaptive' (24:2.4:1.6) Nf stoichiometry (not significant) and increased significantly to 355 ± 330k (35.5 h) with 'luxury' (7:3:2) Nf subunit stoichiometry (p < 0.0001 for each comparison). Longitudinal disease progression-related energy consumption was highest with a 'luxury' (7:3:2) Nf stoichiometry. Therefore, an energy and time-saving option for motor neurons is to shift protein expression from larger to smaller (cheaper) subunits, at little or no costs on a protein structural level, to compensate for increased energy demands.
Neurofilament proteins (Nf) are a biomarker of disease progression in amyotrophic lateral sclerosis (ALS). This study investigated whether there are major differences in expression from in vivo measurements of neurofilament isoforms, from the light chain, NfL (68 kDa), compared with larger proteins, the medium chain (NfM, 150 kDa) and the heavy (NfH, 200‐210 kDa) chains in ALS patients and healthy controls. New immunological methods were combined with Nf subunit stoichiometry calculations and Monte Carlo simulations of a coarse‐grained Nf brush model. Based on a physiological Nf subunit stoichiometry of 7 : 3 : 2 (NfL:NfM:NfH), we found an ‘adaptive’ Nf subunit stoichiometry of 24 : 2.4 : 1.6 in ALS. Adaptive Nf stoichiometry preserved NfL gyration radius in the Nf brush model. The energy and time requirements for Nf translation were 56 ± 27k ATP (5.6 h) in control subjects compared to 123 ± 102k (12.3 h) in ALS with ‘adaptive’ (24:2.4:1.6) Nf stoichiometry (not significant) and increased significantly to 355 ± 330k (35.5 h) with ‘luxury’ (7:3:2) Nf subunit stoichiometry (p < 0.0001 for each comparison). Longitudinal disease progression‐related energy consumption was highest with a ‘luxury’ (7:3:2) Nf stoichiometry. Therefore, an energy and time‐saving option for motor neurons is to shift protein expression from larger to smaller (cheaper) subunits, at little or no costs on a protein structural level, to compensate for increased energy demands. This study describes a novel concept, adaptive protein stoichiometry, which provides neurons with an efficient strategy to slow neurodegeneration. The data supporting this conclusion come from protein concentrations measured in patients suffering from a rapid neurodegenerative condition, amyotrophic lateral sclerosis (synonymous motor neuron disease, Lou Gehrig disease). Extrapolation to a much boarder disease spectrum is conceivable as ‘adaptive protein stoichiometry’ is based on the fundamental principle of ATP and time requirements for transcription. The results of present data on the neurofilament triplet protein should be applicable to other heteropolymers and offer a new conceptional framework for developing antisense therapies.
Author Chang, Rakwoo
Adiutori, Rocco
Petzold, Axel
Malaspina, Andrea
Ceroni, Mauro
Zucchi, Elisabetta
Greensmith, Linda
Lu, Ching‐Hua
Cho, Yunju
Zubiri, Irene
Cereda, Cristina
Pansarasa, Orietta
AuthorAffiliation 3 Department of Neurology China Medical University Hospital Taichung City Taiwan
11 Amsterdam UMC Departments of Neurology and Ophthalmology De Boelelaan Amsterdam NL
1 Centre for Neuroscience and Trauma Blizard Institute, Barts and the London School of Medicine and Dentistry Queen Mary University of London London UK
10 Moorfields Eye Hospital London UK
5 Department of Brain and Behavioural Sciences University of Pavia Pavia Italy
4 Department of Chemistry Kwangwoon University Seoul Korea
2 Center of Genomic and post‐Genomic IRCCS Mondino Foundation Pavia Italy
8 Department of Neuromuscular Diseases MRC Centre for Neuromuscular Diseases Queen Square London UK
9 The National Hospital for Neurology and Neurosurgery Queen Square London UK
6 General Neurology Unit IRCCS Mondino Foundation Pavia Italy
7 Sobell Department of Motor Neuroscience and Movement Disorders MRC Centre for Neuromuscular Diseases UCL Institute of Neurology University College London London UK
AuthorAffiliation_xml – name: 1 Centre for Neuroscience and Trauma Blizard Institute, Barts and the London School of Medicine and Dentistry Queen Mary University of London London UK
– name: 2 Center of Genomic and post‐Genomic IRCCS Mondino Foundation Pavia Italy
– name: 4 Department of Chemistry Kwangwoon University Seoul Korea
– name: 9 The National Hospital for Neurology and Neurosurgery Queen Square London UK
– name: 3 Department of Neurology China Medical University Hospital Taichung City Taiwan
– name: 5 Department of Brain and Behavioural Sciences University of Pavia Pavia Italy
– name: 7 Sobell Department of Motor Neuroscience and Movement Disorders MRC Centre for Neuromuscular Diseases UCL Institute of Neurology University College London London UK
– name: 8 Department of Neuromuscular Diseases MRC Centre for Neuromuscular Diseases Queen Square London UK
– name: 6 General Neurology Unit IRCCS Mondino Foundation Pavia Italy
– name: 10 Moorfields Eye Hospital London UK
– name: 11 Amsterdam UMC Departments of Neurology and Ophthalmology De Boelelaan Amsterdam NL
Author_xml – sequence: 1
  givenname: Elisabetta
  surname: Zucchi
  fullname: Zucchi, Elisabetta
  organization: IRCCS Mondino Foundation
– sequence: 2
  givenname: Ching‐Hua
  surname: Lu
  fullname: Lu, Ching‐Hua
  organization: China Medical University Hospital
– sequence: 3
  givenname: Yunju
  surname: Cho
  fullname: Cho, Yunju
  organization: Kwangwoon University
– sequence: 4
  givenname: Rakwoo
  surname: Chang
  fullname: Chang, Rakwoo
  organization: Kwangwoon University
– sequence: 5
  givenname: Rocco
  surname: Adiutori
  fullname: Adiutori, Rocco
  organization: Queen Mary University of London
– sequence: 6
  givenname: Irene
  surname: Zubiri
  fullname: Zubiri, Irene
  organization: Queen Mary University of London
– sequence: 7
  givenname: Mauro
  surname: Ceroni
  fullname: Ceroni, Mauro
  organization: IRCCS Mondino Foundation
– sequence: 8
  givenname: Cristina
  surname: Cereda
  fullname: Cereda, Cristina
  organization: IRCCS Mondino Foundation
– sequence: 9
  givenname: Orietta
  surname: Pansarasa
  fullname: Pansarasa, Orietta
  organization: IRCCS Mondino Foundation
– sequence: 10
  givenname: Linda
  surname: Greensmith
  fullname: Greensmith, Linda
  organization: University College London
– sequence: 11
  givenname: Andrea
  surname: Malaspina
  fullname: Malaspina, Andrea
  organization: Queen Mary University of London
– sequence: 12
  givenname: Axel
  orcidid: 0000-0002-0344-9749
  surname: Petzold
  fullname: Petzold, Axel
  email: a.petzold@ucl.ac.uk
  organization: De Boelelaan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/29959860$$D View this record in MEDLINE/PubMed
BookMark eNp1kUtv1DAUhS3Uik4LC_4AssQGFmn9ihOzQKpGvKoKNrC2HOdm6lFiD7bTav59PZ0pggq8sXT93eNz7zlFRz54QOgVJee0nIu1t-dU1II9QwsqGloJWqsjtCCEsYoTwU7QaUprQqgUkj5HJ0ypWrWSLFB_iaeQQ8Qe5hg8TjmaDKstzgEncws4uwmw8T0GD7HUnd-jPax2FZNd8O-x6c0mu4JvYsjgdjrB2RsXJshx-wIdD2ZM8PJwn6Gfnz7-WH6prr9__rq8vK6sEJxVnbSC14McDGnaoTOdaQSwVtleMtsp0ytBasJrxWxj1UClMR03g2Bd3XJWAz9DH_a6m7mboLfgyzSj3kQ3mbjVwTj994t3N3oVbrWkTS04KQJvDwIx_JohZT25ZGEcjYcwJ82IZLuvJC3omyfoOszRl_E0o7QsXnHeFur1n45-W3kMoAAXe8DGkFKEQVuXH5ZaDLpRU6J3EesSsX6IuHS8e9LxKPov9qB-50bY_h_UV9-W-4577O63YQ
CitedBy_id crossref_primary_10_1093_brain_awab382
crossref_primary_10_17116_jnevro2019119107
crossref_primary_10_1002_acn3_51428
crossref_primary_10_1080_21678421_2019_1646769
crossref_primary_10_3390_ijms252111661
crossref_primary_10_1038_s41582_018_0058_z
crossref_primary_10_1038_s41582_023_00891_2
crossref_primary_10_3389_fnins_2021_689938
crossref_primary_10_1002_acn3_51234
crossref_primary_10_1038_s41582_024_00955_x
crossref_primary_10_1111_jnc_15682
crossref_primary_10_1007_s12035_019_01698_3
crossref_primary_10_3390_genes15040496
crossref_primary_10_1111_ene_16192
crossref_primary_10_1111_jnc_16261
crossref_primary_10_1080_21678421_2024_2428930
crossref_primary_10_1038_s41598_022_18942_x
crossref_primary_10_1002_ana_26265
crossref_primary_10_1167_tvst_13_9_30
crossref_primary_10_17116_jnevro20191191027
crossref_primary_10_1111_ane_13698
crossref_primary_10_1186_s13024_020_00406_3
Cites_doi 10.1016/j.neuron.2016.05.018
10.1136/jnnp-2014-308946
10.1177/1352458510364196
10.1001/jamaneurol.2016.5398
10.1016/j.jmb.2009.06.045
10.1002/ana.20736
10.1136/jnnp-2012-303768
10.1212/01.wnl.0000203120.85850.54
10.1016/j.clinbiochem.2009.03.020
10.1016/j.cell.2004.08.026
10.1038/nrn752
10.1002/ana.24980
10.1016/S1359-0294(03)00010-4
10.1002/ana.24552
10.1152/physrev.1997.77.3.731
10.1371/journal.pone.0040998
10.1074/jbc.M115.700385
10.1080/21678421.2016.1241279
10.1016/S1474-4422(13)70233-3
10.1073/pnas.95.16.9626
10.1529/biophysj.106.095323
10.1212/WNL.0000000000004761
10.1038/nrdp.2017.71
10.1136/jnnp-2013-305494
10.1016/S1474-4422(16)00070-3
10.3109/17482968.2011.627589
10.1016/j.neurobiolaging.2018.02.017
10.1038/nrneurol.2011.151
10.3389/fnagi.2016.00290
10.1016/j.jns.2008.12.037
10.1038/nmat2566
10.3389/fncel.2015.00248
10.1038/nature12481
10.1529/biophysj.107.104695
10.1159/000101843
10.1093/brain/awq360
10.1016/S0079-6603(08)60823-5
10.1007/s12035-008-8033-0
10.1016/S1093-3263(00)00138-8
10.1016/j.jim.2009.09.014
10.1038/nrneurol.2014.228
10.1038/nrneurol.2014.37
10.1002/ana.22438
10.1016/S0006-3495(02)75581-1
10.1515/cclm-2015-1195
10.1371/journal.pone.0075091
10.1042/BST20120101
10.1111/j.1471-4159.1987.tb01002.x
10.1111/j.1471-4159.1985.tb05442.x
10.1136/jnnp.2005.085175
10.1016/j.jns.2011.04.023
10.4155/bio-2016-0114
10.1016/S0962-8924(97)01049-0
10.1016/j.jns.2005.03.015
10.1212/WNL.0000000000001642
10.1007/s00415-017-8730-6
10.1007/BF00966828
10.1136/jnnp-2017-316605
10.1093/brain/awp046
10.1016/S0092-8674(01)00244-6
10.1038/msb.2009.68
10.1212/WNL.0b013e3181c47cc2
10.1038/375061a0
10.1016/0092-8674(92)90183-D
10.1016/j.jneumeth.2010.11.026
10.1126/science.aac4354
10.1136/jnnp-2014-309827
10.1016/j.brainresbull.2016.09.002
10.1212/WNL.0000000000004029
10.1111/j.1471-4159.2011.07224.x
10.1016/j.nbd.2017.04.007
10.1016/j.jmb.2010.11.022
10.1080/14656566.2016.1202919
10.1002/ana.25143
ContentType Journal Article
Copyright 2018 The Authors. published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry
2018 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.
Copyright © 2018 International Society for Neurochemistry
Copyright_xml – notice: 2018 The Authors. published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry
– notice: 2018 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.
– notice: Copyright © 2018 International Society for Neurochemistry
DBID 24P
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
7QR
7TK
7U7
7U9
8FD
C1K
FR3
H94
P64
7X8
5PM
DOI 10.1111/jnc.14542
DatabaseName Wiley Online Library Open Access
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
Chemoreception Abstracts
Neurosciences Abstracts
Toxicology Abstracts
Virology and AIDS Abstracts
Technology Research Database
Environmental Sciences and Pollution Management
Engineering Research Database
AIDS and Cancer Research Abstracts
Biotechnology and BioEngineering Abstracts
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Virology and AIDS Abstracts
Technology Research Database
Toxicology Abstracts
AIDS and Cancer Research Abstracts
Chemoreception Abstracts
Engineering Research Database
Neurosciences Abstracts
Biotechnology and BioEngineering Abstracts
Environmental Sciences and Pollution Management
MEDLINE - Academic
DatabaseTitleList Virology and AIDS Abstracts
MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
Chemistry
DocumentTitleAlternate E. Zucchi et al
EISSN 1471-4159
EndPage 641
ExternalDocumentID PMC6175430
29959860
10_1111_jnc_14542
JNC14542
Genre article
Research Support, Non-U.S. Gov't
Journal Article
GrantInformation_xml – fundername: National Research Foundation of Korea
  funderid: 2015R1D1A1A01058045
– fundername: National Institute for Health Research (NIHR) Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust
– fundername: UK MND Association
– fundername: UCL Institute of Ophthalmology
– fundername: Korea Institute of Science and Technology Information
  funderid: KSC‐2017‐C3‐0003
– fundername: Motor Neurone Disease Association
  grantid: MALASPINA/APR13/817-791
– fundername: Motor Neurone Disease Association
  grantid: TURNER/OCT15/972-797
– fundername: Korea Institute of Science and Technology Information
  grantid: KSC‐2017‐C3‐0003
– fundername: National Research Foundation of Korea
  grantid: 2015R1D1A1A01058045
GroupedDBID ---
-~X
.3N
.55
.GA
.GJ
.Y3
05W
0R~
10A
1OB
1OC
24P
29L
2WC
31~
33P
36B
3SF
4.4
41~
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5HH
5LA
5RE
5VS
66C
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AAHQN
AAIPD
AAMNL
AANHP
AANLZ
AAONW
AASGY
AAXRX
AAYCA
AAYJJ
AAZKR
ABCQN
ABCUV
ABEML
ABIVO
ABLJU
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOD
ACGOF
ACIWK
ACMXC
ACNCT
ACPOU
ACPRK
ACRPL
ACSCC
ACXBN
ACXQS
ACYXJ
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADNMO
ADOZA
ADXAS
ADZMN
AEEZP
AEGXH
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFRAH
AFWVQ
AFZJQ
AHBTC
AHEFC
AI.
AIACR
AIAGR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
ALVPJ
AMBMR
AMYDB
ASPBG
ATUGU
AVWKF
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DC6
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
E3Z
EBS
EJD
EMOBN
ESX
EX3
F00
F01
F04
F5P
FEDTE
FIJ
FUBAC
FZ0
G-S
G.N
GAKWD
GODZA
GX1
H.X
HF~
HGLYW
HH5
HVGLF
HZI
HZ~
IH2
IHE
IPNFZ
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MVM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
TEORI
TWZ
UB1
V8K
VH1
W8V
W99
WBKPD
WIH
WIJ
WIK
WIN
WNSPC
WOHZO
WOW
WQJ
WRC
WUP
WXI
WXSBR
WYISQ
X7M
XG1
XJT
YFH
YNH
YOC
YUY
ZGI
ZXP
ZZTAW
~IA
~KM
~WT
AAYXX
AEYWJ
AGHNM
AGQPQ
AGYGG
CITATION
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
CGR
CUY
CVF
ECM
EIF
NPM
7QR
7TK
7U7
7U9
8FD
C1K
FR3
H94
P64
7X8
5PM
ID FETCH-LOGICAL-c4432-b6c435f6fa078fbaba74e289cd62cb9ad940503592c7c9f16aab3af42b58325e3
IEDL.DBID DR2
ISSN 0022-3042
1471-4159
IngestDate Thu Aug 21 18:04:53 EDT 2025
Thu Jul 10 17:56:11 EDT 2025
Fri Jul 25 19:42:23 EDT 2025
Mon Jul 21 06:03:20 EDT 2025
Thu Apr 24 23:06:17 EDT 2025
Tue Jul 01 04:39:23 EDT 2025
Wed Jan 22 16:44:45 EST 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 5
Keywords ALS
neurodegeneration
stoichiometry
neurofilaments
energy
Language English
License Attribution
2018 The Authors. Journal of Neurochemistry published by John Wiley & Sons Ltd on behalf of International Society for Neurochemistry.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4432-b6c435f6fa078fbaba74e289cd62cb9ad940503592c7c9f16aab3af42b58325e3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally to this work.
ORCID 0000-0002-0344-9749
OpenAccessLink https://proxy.k.utb.cz/login?url=https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjnc.14542
PMID 29959860
PQID 2110229338
PQPubID 31528
PageCount 11
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_6175430
proquest_miscellaneous_2062832561
proquest_journals_2110229338
pubmed_primary_29959860
crossref_citationtrail_10_1111_jnc_14542
crossref_primary_10_1111_jnc_14542
wiley_primary_10_1111_jnc_14542_JNC14542
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate September 2018
2018-09-00
20180901
PublicationDateYYYYMMDD 2018-09-01
PublicationDate_xml – month: 09
  year: 2018
  text: September 2018
PublicationDecade 2010
PublicationPlace England
PublicationPlace_xml – name: England
– name: New York
– name: Hoboken
PublicationTitle Journal of neurochemistry
PublicationTitleAlternate J Neurochem
PublicationYear 2018
Publisher Blackwell Publishing Ltd
John Wiley and Sons Inc
Publisher_xml – name: Blackwell Publishing Ltd
– name: John Wiley and Sons Inc
References 2010; 16
2017; 82
2017; 3
2009; 42
2011; 117
2017; 88
2008; 38
1992; 17
2000; 1
2018; 83
1995; 375
2018; 89
2013; 8
2011; 195
2012; 13
2001; 104
2009; 279
2016; 79
1997; 7
2017; 74
2011; 405
2015; 84
2006; 66
2015; 86
2003; 8
2015; 87
2001; 19
2010; 352
2016; 87
2016; 353
2014; 13
2007; 4
2011; 69
1998; 95
2010; 9
2014; 10
1987; 49
2007b; 93
2018; 265
2005; 233
2013; 84
2013; 501
2015; 11
2006; 59
2016; 54
2009; 132
2002; 3
2002; 82
1998; 61
2016; 126
2007a; 93
2016; 91
2014; 85
1985; 44
2018; 67
2016; 17
2015; 9
2016; 15
2006a; 77
2011; 134
2011; 7
2011; 307
2009; 73
1997; 77
2009; 391
2018; 90
1992; 68
2016
2017; 18
2009; 5
2012; 7
2016; 291
2004; 118
2017; 104
2016; 8
2012; 40
e_1_2_8_28_1
e_1_2_8_24_1
e_1_2_8_47_1
e_1_2_8_26_1
e_1_2_8_49_1
e_1_2_8_68_1
e_1_2_8_3_1
e_1_2_8_5_1
e_1_2_8_7_1
e_1_2_8_9_1
e_1_2_8_20_1
e_1_2_8_43_1
e_1_2_8_66_1
e_1_2_8_22_1
e_1_2_8_45_1
e_1_2_8_62_1
e_1_2_8_41_1
e_1_2_8_60_1
e_1_2_8_17_1
e_1_2_8_13_1
e_1_2_8_36_1
e_1_2_8_59_1
e_1_2_8_15_1
e_1_2_8_38_1
e_1_2_8_57_1
e_1_2_8_70_1
Disanto G. (e_1_2_8_19_1) 2015; 87
e_1_2_8_32_1
e_1_2_8_55_1
e_1_2_8_78_1
e_1_2_8_34_1
e_1_2_8_53_1
e_1_2_8_76_1
e_1_2_8_51_1
e_1_2_8_74_1
e_1_2_8_30_1
e_1_2_8_72_1
e_1_2_8_29_1
e_1_2_8_25_1
e_1_2_8_46_1
e_1_2_8_27_1
e_1_2_8_48_1
Steinacker P. (e_1_2_8_64_1) 2016; 87
e_1_2_8_69_1
Brooks B. R. (e_1_2_8_11_1) 2000; 1
e_1_2_8_2_1
e_1_2_8_4_1
e_1_2_8_6_1
e_1_2_8_8_1
e_1_2_8_21_1
e_1_2_8_42_1
e_1_2_8_67_1
e_1_2_8_23_1
e_1_2_8_44_1
e_1_2_8_65_1
e_1_2_8_63_1
e_1_2_8_40_1
e_1_2_8_61_1
e_1_2_8_18_1
e_1_2_8_39_1
e_1_2_8_14_1
e_1_2_8_35_1
e_1_2_8_16_1
e_1_2_8_37_1
e_1_2_8_58_1
e_1_2_8_79_1
Zetterberg H. (e_1_2_8_77_1) 2016
e_1_2_8_10_1
e_1_2_8_31_1
e_1_2_8_56_1
e_1_2_8_12_1
e_1_2_8_33_1
e_1_2_8_54_1
e_1_2_8_75_1
e_1_2_8_52_1
e_1_2_8_73_1
e_1_2_8_50_1
e_1_2_8_71_1
References_xml – volume: 61
  start-page: 1
  year: 1998
  end-page: 23
  article-title: Neurofilaments in health and disease
  publication-title: Prog. Nucleic Acid Res. Mol. Biol.
– volume: 233
  start-page: 183
  year: 2005
  end-page: 198
  article-title: Neurofilament phosphoforms: surrogate markers for axonal injury, degeneration and loss
  publication-title: J. Neurol. Sci.
– volume: 265
  start-page: 510
  year: 2018
  end-page: 521
  article-title: CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis
  publication-title: J. Neurol.
– volume: 11
  start-page: 11
  year: 2015
  end-page: 24
  article-title: Disturbed mitochondrial dynamics and neurodegenerative disorders
  publication-title: Nat. Rev. Neurol.
– volume: 17
  start-page: 1005
  year: 1992
  end-page: 1009
  article-title: Proteolysis of filament proteins in glial and neuronal cells after in vivo stimulation of hippocampal NMDA receptors
  publication-title: Neurochem. Res.
– volume: 3
  start-page: 17071
  year: 2017
  article-title: Amyotrophic lateral sclerosis
  publication-title: Nat. Rev. Dis. Prim.
– volume: 7
  start-page: 243
  year: 1997
  end-page: 249
  article-title: Neurofilaments and motor neuron disease
  publication-title: Trends Cell Biol.
– volume: 279
  start-page: 76
  year: 2009
  end-page: 79
  article-title: Longitudinal one‐year study of levels and stoichiometry of neurofilament heavy and light chain concentrations in CSF in patients with multiple system atrophy
  publication-title: J. Neurol. Sci.
– volume: 38
  start-page: 27
  year: 2008
  end-page: 65
  article-title: Review of the multiple aspects of neurofilament functions, and their possible contribution to neurodegeneration
  publication-title: Mol. Neurobiol.
– volume: 501
  start-page: 45
  year: 2013
  end-page: 51
  article-title: Self‐propagation of pathogenic protein aggregates in neurodegenerative diseases
  publication-title: Nature
– year: 2016
  article-title: Neurological Biomarkers
  publication-title: Rev. Cell Biol. Mol. Med.
– volume: 10
  start-page: 225
  year: 2014
  end-page: 238
  article-title: Mechanisms of neurodegeneration and axonal dysfunction in multiple sclerosis
  publication-title: Nat. Rev. Neurol.
– volume: 13
  start-page: 1
  year: 2012
  end-page: 10
  article-title: Roadmap and standard operating procedures for biobanking and discovery of neurochemical markers in ALS
  publication-title: Amyotroph Lateral Scler.
– volume: 86
  start-page: 1388
  year: 2015
  end-page: 1390
  article-title: The prognostic value of CSF neurofilaments in multiple sclerosis at 15‐year follow‐up
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 307
  start-page: 132
  year: 2011
  end-page: 138
  article-title: Neurofilament stoichiometry simulations during neurodegeneration suggest a remarkable self‐sufficient and stable in vivo protein structure
  publication-title: J. Neurol. Sci.
– volume: 68
  start-page: 451
  year: 1992
  end-page: 463
  article-title: Local modulation of neurofilament phosphorylation, axonal caliber, and slow axonal transport by myelinating Schwann cells
  publication-title: Cell
– volume: 13
  start-page: 113
  year: 2014
  end-page: 126
  article-title: Body fluid biomarkers in multiple sclerosis
  publication-title: Lancet. Neurol.
– volume: 117
  start-page: 528
  year: 2011
  end-page: 537
  article-title: Combination of neurofilament heavy chain and complement C3 as CSF biomarkers for ALS
  publication-title: J. Neurochem.
– volume: 8
  start-page: e75091
  year: 2013
  article-title: Increased neurofilament light chain blood levels in neurodegenerative neurological diseases
  publication-title: PLoS ONE
– volume: 405
  start-page: 1101
  year: 2011
  end-page: 1118
  article-title: Phosphorylation‐mediated conformational changes in the mouse neurofilament architecture: insight from a neurofilament brush model
  publication-title: J. Mol. Biol.
– volume: 85
  start-page: 274
  year: 2014
  end-page: 278
  article-title: Immune reactivity to neurofilament proteins in the clinical staging of amyotrophic lateral sclerosis
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 104
  start-page: 581
  year: 2001
  end-page: 591
  article-title: Amyotrophic lateral sclerosis. unfolding the toxicity of the misfolded
  publication-title: Cell
– volume: 9
  start-page: 248
  year: 2015
  article-title: Seeking homeostasis: temporal trends in respiration, oxidation, and calcium in SOD1 G93A Amyotrophic Lateral Sclerosis mice
  publication-title: Front. Cell. Neurosci.
– volume: 8
  start-page: 40
  year: 2003
  end-page: 47
  article-title: Assembly and structure of neurofilaments
  publication-title: Curr. Opin. Colloid Interface Sci.
– volume: 17
  start-page: 1669
  year: 2016
  end-page: 1682
  article-title: Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection
  publication-title: Expert Opin. Pharmacother.
– volume: 15
  start-page: 673
  year: 2016
  end-page: 684
  article-title: CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta‐analysis
  publication-title: Lancet Neurol.
– volume: 88
  start-page: 2302
  year: 2017
  end-page: 2309
  article-title: Neurofilament markers for ALS correlate with extent of upper and lower motor neuron disease
  publication-title: Neurology
– volume: 66
  start-page: 852
  year: 2006
  end-page: 856
  article-title: Axonal damage markers in cerebrospinal fluid are increased in ALS
  publication-title: Neurology
– volume: 19
  start-page: 26
  year: 2001
  end-page: 59
  article-title: Intrinsically disordered protein
  publication-title: J. Mol. Graph. Model.
– volume: 74
  start-page: 525
  year: 2017
  end-page: 532
  article-title: Diagnostic and prognostic biomarkers in amyotrophic lateral sclerosis: neurofilament light chain levels in definite subtypes of disease
  publication-title: JAMA Neurol.
– volume: 7
  start-page: e40998
  year: 2012
  article-title: Plasma neurofilament heavy chain levels correlate to markers of late stage disease progression and treatment response in SOD1(G93A) mice that model ALS
  publication-title: PLoS ONE
– volume: 77
  start-page: 731
  year: 1997
  end-page: 758
  article-title: Cellular energy utilization and molecular origin of standard metabolic rate in mammals
  publication-title: Physiol. Rev.
– volume: 8
  start-page: 290
  year: 2016
  article-title: Neurofilaments in CSF as diagnostic biomarkers in motor neuron disease: a meta‐analysis
  publication-title: Front. Aging Neurosci.
– volume: 4
  start-page: 185
  year: 2007
  end-page: 194
  article-title: A systematic review and meta‐analysis of CSF neurofilament protein levels as biomarkers in dementia
  publication-title: Neurodegener. Dis.
– volume: 353
  start-page: aac4354
  year: 2016
  article-title: In vivo aspects of protein folding and quality control
  publication-title: Science
– volume: 352
  start-page: 23
  year: 2010
  end-page: 31
  article-title: Neurofilament ELISA validation
  publication-title: J. Immunol. Methods
– volume: 69
  start-page: 1065‐6‐7
  year: 2011
  article-title: The neurofilament light chain is not stable in vitro
  publication-title: Ann. Neurol.
– volume: 89
  start-page: 367
  year: 2018
  end-page: 373
  article-title: Comparison of elevated phosphorylated neurofilament heavy chains in serum and cerebrospinal fluid of patients with amyotrophic lateral sclerosis
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 59
  start-page: 478
  year: 2006
  end-page: 489
  article-title: Mitochondrial dysfunction as a cause of axonal degeneration in multiple sclerosis patients
  publication-title: Ann. Neurol.
– volume: 90
  start-page: e22
  year: 2018
  end-page: e30
  article-title: Multicenter evaluation of neurofilaments in early symptom onset amyotrophic lateral sclerosis
  publication-title: Neurology
– volume: 16
  start-page: 549
  year: 2010
  end-page: 554
  article-title: Cerebrospinal fluid ATP metabolites in multiple sclerosis
  publication-title: Mult. Scler.
– volume: 86
  start-page: 667
  year: 2015
  end-page: 673
  article-title: Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis. The expanding syndrome of amyotrophic lateral sclerosis: a clinical and molecular odyssey
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 67
  start-page: 21
  year: 2018
  end-page: 22
  article-title: Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis
  publication-title: Neurobiol. Aging
– volume: 291
  start-page: 4356
  year: 2016
  end-page: 4373
  article-title: Selective inhibition of the mitochondrial permeability transition pore protects against neurodegeneration in experimental multiple sclerosis
  publication-title: J. Biol. Chem.
– volume: 83
  start-page: 258
  year: 2018
  end-page: 268
  article-title: Cerebrospinal fluid macrophage biomarkers in amyotrophic lateral sclerosis
  publication-title: Ann. Neurol.
– volume: 132
  start-page: 1161
  year: 2009
  end-page: 1174
  article-title: Mitochondrial changes within axons in multiple sclerosis
  publication-title: Brain
– volume: 84
  start-page: 2247
  year: 2015
  end-page: 2257
  article-title: Neurofilament light chain: a prognostic biomarker in amyotrophic lateral sclerosis
  publication-title: Neurology
– volume: 40
  start-page: 1027
  year: 2012
  end-page: 1031
  article-title: Structures and interactions in “bottlebrush” neurofilaments: the role of charged disordered proteins in forming hydrogel networks
  publication-title: Biochem. Soc. Trans.
– volume: 82
  start-page: 2360
  year: 2002
  end-page: 2372
  article-title: Relating interactions between neurofilaments to the structure of axonal neurofilament distributions through polymer brush models
  publication-title: Biophys. J .
– volume: 93
  start-page: 1421
  year: 2007a
  end-page: 30
  article-title: A self‐consistent field analysis of the neurofilament brush with amino‐acid resolution
  publication-title: Biophys. J .
– volume: 79
  start-page: 152
  year: 2016
  end-page: 158
  article-title: Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis
  publication-title: Ann. Neurol.
– volume: 134
  start-page: 464
  year: 2011
  end-page: 483
  article-title: In vivo monitoring of neuronal loss in traumatic brain injury: a microdialysis study
  publication-title: Brain
– volume: 87
  start-page: 126
  year: 2015
  end-page: 129
  article-title: Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 91
  start-page: 56
  year: 2016
  end-page: 66
  article-title: Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases
  publication-title: Neuron
– volume: 375
  start-page: 61
  year: 1995
  end-page: 64
  article-title: Defective axonal transport in a transgenic mouse model of amyotrophic lateral sclerosis
  publication-title: Nature
– volume: 95
  start-page: 9626
  year: 1998
  end-page: 30
  article-title: Protective effect of neurofilament heavy gene overexpression in motor neuron disease induced by mutant superoxide dismutase
  publication-title: Proc. Natl Acad. Sci. USA
– volume: 54
  start-page: 1655
  year: 2016
  end-page: 1661
  article-title: Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa
  publication-title: Clin. Chem. Lab. Med.
– volume: 87
  start-page: 12
  year: 2016
  end-page: 20
  article-title: Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients
  publication-title: J. Neurol. Neurosurg.
– volume: 84
  start-page: 467
  year: 2013
  end-page: 472
  article-title: Phosphorylated neurofilament heavy subunit (pNF‐H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 195
  start-page: 143
  year: 2011
  end-page: 150
  article-title: A method to solubilise protein aggregates for immunoassay quantification which overcomes the neurofilament hook effect
  publication-title: J. Neurosci. Methods
– volume: 126
  start-page: 334
  year: 2016
  end-page: 346
  article-title: Specialized roles of neurofilament proteins in synapses: relevance to neuropsychiatric disorders
  publication-title: Brain Res. Bull.
– volume: 42
  start-page: 1001
  year: 2009
  end-page: 1006
  article-title: Increase of uric acid and purine compounds in biological fluids of multiple sclerosis patients
  publication-title: Clin. Biochem.
– volume: 44
  start-page: 502
  year: 1985
  end-page: 509
  article-title: An immunoblot study of neurofilament degradation in situ and during calcium‐activated proteolysis
  publication-title: J. Neurochem.
– volume: 18
  start-page: 112
  year: 2017
  end-page: 119
  article-title: Diagnostic and prognostic significance of neurofilament light chain NF‐L, but not progranulin and S100B, in the course of amyotrophic lateral sclerosis: data from the German MND‐net
  publication-title: Amyotroph. Lateral Scler. Frontotemporal Degener.
– volume: 7
  start-page: 631
  year: 2011
  end-page: 638
  article-title: Biomarkers in amyotrophic lateral sclerosis: opportunities and limitations
  publication-title: Nat. Rev. Neurol.
– volume: 8
  start-page: 2243
  year: 2016
  end-page: 2254
  article-title: Multicenter immunoassay validation of cerebrospinal fluid neurofilament light: a biomarker for neurodegeneration
  publication-title: Bioanalysis
– volume: 93
  start-page: 1452
  year: 2007b
  end-page: 1463
  article-title: Effect of the ionic strength and pH on the equilibrium structure of a neurofilament brush
  publication-title: Biophys. J .
– volume: 5
  start-page: 314
  year: 2009
  article-title: Ribosome and transcript copy numbers, polysome occupancy and enzyme dynamics in Arabidopsis
  publication-title: Mol. Syst. Biol.
– volume: 3
  start-page: 216
  year: 2002
  end-page: 227
  article-title: Innate immunity: the missing link in neuroprotection and neurodegeneration?
  publication-title: Nat. Rev. Neurosci.
– volume: 118
  start-page: 687
  year: 2004
  end-page: 698
  article-title: Neuroprotection in ischemia: blocking calcium‐permeable acid‐sensing ion channels
  publication-title: Cell
– volume: 9
  start-page: 40
  year: 2010
  end-page: 46
  article-title: Gel‐expanded to gel‐condensed transition in neurofilament networks revealed by direct force measurements
  publication-title: Nat. Mater.
– volume: 73
  start-page: 1914
  year: 2009
  end-page: 1922
  article-title: A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking
  publication-title: Neurology
– volume: 1
  start-page: 293
  year: 2000
  end-page: 299
  article-title: Amyotroph Lateral Scler Other Motor Neuron Disord
  publication-title: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
– volume: 82
  start-page: 139
  year: 2017
  end-page: 146
  article-title: Phosphorylated neurofilament heavy chain: a biomarker of survival for ‐associated amyotrophic lateral sclerosis
  publication-title: Ann. Neurol.
– volume: 391
  start-page: 648
  year: 2009
  end-page: 660
  article-title: Structural properties of neurofilament sidearms: sequence‐based modeling of neurofilament architecture
  publication-title: J. Mol. Biol.
– volume: 77
  start-page: 753
  year: 2006a
  end-page: 759
  article-title: Axonal damage and outcome in subarachnoid haemorrhage
  publication-title: J. Neurol. Neurosurg. Psychiatry
– volume: 104
  start-page: 73
  year: 2017
  end-page: 84
  article-title: NF‐L in cerebrospinal fluid and serum is a biomarker of neuronal damage in an inducible mouse model of neurodegeneration
  publication-title: Neurobiol. Dis.
– volume: 49
  start-page: 1375
  year: 1987
  end-page: 1378
  article-title: A rapid HPLC method to separate the triplet proteins of neurofilament
  publication-title: J. Neurochem.
– ident: e_1_2_8_3_1
  doi: 10.1016/j.neuron.2016.05.018
– ident: e_1_2_8_69_1
  doi: 10.1136/jnnp-2014-308946
– ident: e_1_2_8_40_1
  doi: 10.1177/1352458510364196
– ident: e_1_2_8_24_1
  doi: 10.1001/jamaneurol.2016.5398
– year: 2016
  ident: e_1_2_8_77_1
  article-title: Neurological Biomarkers
  publication-title: Rev. Cell Biol. Mol. Med.
– ident: e_1_2_8_14_1
  doi: 10.1016/j.jmb.2009.06.045
– ident: e_1_2_8_21_1
  doi: 10.1002/ana.20736
– ident: e_1_2_8_9_1
  doi: 10.1136/jnnp-2012-303768
– ident: e_1_2_8_10_1
  doi: 10.1212/01.wnl.0000203120.85850.54
– ident: e_1_2_8_2_1
  doi: 10.1016/j.clinbiochem.2009.03.020
– ident: e_1_2_8_75_1
  doi: 10.1016/j.cell.2004.08.026
– ident: e_1_2_8_47_1
  doi: 10.1038/nrn752
– ident: e_1_2_8_27_1
  doi: 10.1002/ana.24980
– ident: e_1_2_8_30_1
  doi: 10.1016/S1359-0294(03)00010-4
– ident: e_1_2_8_74_1
  doi: 10.1002/ana.24552
– ident: e_1_2_8_61_1
  doi: 10.1152/physrev.1997.77.3.731
– ident: e_1_2_8_43_1
  doi: 10.1371/journal.pone.0040998
– ident: e_1_2_8_73_1
  doi: 10.1074/jbc.M115.700385
– ident: e_1_2_8_65_1
  doi: 10.1080/21678421.2016.1241279
– ident: e_1_2_8_16_1
  doi: 10.1016/S1474-4422(13)70233-3
– ident: e_1_2_8_17_1
  doi: 10.1073/pnas.95.16.9626
– ident: e_1_2_8_78_1
  doi: 10.1529/biophysj.106.095323
– ident: e_1_2_8_22_1
  doi: 10.1212/WNL.0000000000004761
– ident: e_1_2_8_28_1
  doi: 10.1038/nrdp.2017.71
– ident: e_1_2_8_60_1
  doi: 10.1136/jnnp-2013-305494
– ident: e_1_2_8_48_1
  doi: 10.1016/S1474-4422(16)00070-3
– volume: 87
  start-page: 12
  year: 2016
  ident: e_1_2_8_64_1
  article-title: Neurofilaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients
  publication-title: J. Neurol. Neurosurg.
– ident: e_1_2_8_49_1
  doi: 10.3109/17482968.2011.627589
– ident: e_1_2_8_70_1
  doi: 10.1016/j.neurobiolaging.2018.02.017
– ident: e_1_2_8_8_1
  doi: 10.1038/nrneurol.2011.151
– ident: e_1_2_8_41_1
  doi: 10.3389/fnagi.2016.00290
– ident: e_1_2_8_55_1
  doi: 10.1016/j.jns.2008.12.037
– volume: 87
  start-page: 126
  year: 2015
  ident: e_1_2_8_19_1
  article-title: Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome
  publication-title: J. Neurol. Neurosurg. Psychiatry
– ident: e_1_2_8_5_1
  doi: 10.1038/nmat2566
– ident: e_1_2_8_29_1
  doi: 10.3389/fncel.2015.00248
– ident: e_1_2_8_31_1
  doi: 10.1038/nature12481
– ident: e_1_2_8_79_1
  doi: 10.1529/biophysj.107.104695
– ident: e_1_2_8_54_1
  doi: 10.1159/000101843
– ident: e_1_2_8_57_1
  doi: 10.1093/brain/awq360
– ident: e_1_2_8_34_1
  doi: 10.1016/S0079-6603(08)60823-5
– ident: e_1_2_8_50_1
  doi: 10.1007/s12035-008-8033-0
– ident: e_1_2_8_20_1
  doi: 10.1016/S1093-3263(00)00138-8
– ident: e_1_2_8_56_1
  doi: 10.1016/j.jim.2009.09.014
– volume: 1
  start-page: 293
  year: 2000
  ident: e_1_2_8_11_1
  article-title: Amyotroph Lateral Scler Other Motor Neuron Disord
  publication-title: Official Publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases
– ident: e_1_2_8_13_1
  doi: 10.1038/nrneurol.2014.228
– ident: e_1_2_8_23_1
  doi: 10.1038/nrneurol.2014.37
– ident: e_1_2_8_37_1
  doi: 10.1002/ana.22438
– ident: e_1_2_8_39_1
  doi: 10.1016/S0006-3495(02)75581-1
– ident: e_1_2_8_38_1
  doi: 10.1515/cclm-2015-1195
– ident: e_1_2_8_25_1
  doi: 10.1371/journal.pone.0075091
– ident: e_1_2_8_6_1
  doi: 10.1042/BST20120101
– ident: e_1_2_8_35_1
  doi: 10.1111/j.1471-4159.1987.tb01002.x
– ident: e_1_2_8_63_1
  doi: 10.1111/j.1471-4159.1985.tb05442.x
– ident: e_1_2_8_53_1
  doi: 10.1136/jnnp.2005.085175
– ident: e_1_2_8_36_1
  doi: 10.1016/j.jns.2011.04.023
– ident: e_1_2_8_46_1
  doi: 10.4155/bio-2016-0114
– ident: e_1_2_8_32_1
  doi: 10.1016/S0962-8924(97)01049-0
– ident: e_1_2_8_51_1
  doi: 10.1016/j.jns.2005.03.015
– ident: e_1_2_8_44_1
  doi: 10.1212/WNL.0000000000001642
– ident: e_1_2_8_62_1
  doi: 10.1007/s00415-017-8730-6
– ident: e_1_2_8_72_1
  doi: 10.1007/BF00966828
– ident: e_1_2_8_18_1
  doi: 10.1136/jnnp-2017-316605
– ident: e_1_2_8_45_1
  doi: 10.1093/brain/awp046
– ident: e_1_2_8_33_1
  doi: 10.1016/S0092-8674(01)00244-6
– ident: e_1_2_8_58_1
  doi: 10.1038/msb.2009.68
– ident: e_1_2_8_67_1
  doi: 10.1212/WNL.0b013e3181c47cc2
– ident: e_1_2_8_15_1
  doi: 10.1038/375061a0
– ident: e_1_2_8_71_1
  doi: 10.1016/0092-8674(92)90183-D
– ident: e_1_2_8_42_1
  doi: 10.1016/j.jneumeth.2010.11.026
– ident: e_1_2_8_4_1
  doi: 10.1126/science.aac4354
– ident: e_1_2_8_52_1
  doi: 10.1136/jnnp-2014-309827
– ident: e_1_2_8_76_1
  doi: 10.1016/j.brainresbull.2016.09.002
– ident: e_1_2_8_59_1
  doi: 10.1212/WNL.0000000000004029
– ident: e_1_2_8_26_1
  doi: 10.1111/j.1471-4159.2011.07224.x
– ident: e_1_2_8_12_1
  doi: 10.1016/j.nbd.2017.04.007
– ident: e_1_2_8_66_1
  doi: 10.1016/j.jmb.2010.11.022
– ident: e_1_2_8_7_1
  doi: 10.1080/14656566.2016.1202919
– ident: e_1_2_8_68_1
  doi: 10.1002/ana.25143
SSID ssj0016461
Score 2.3877802
Snippet Neurofilament proteins (Nf) are a biomarker of disease progression in amyotrophic lateral sclerosis (ALS). This study investigated whether there are major...
SourceID pubmedcentral
proquest
pubmed
crossref
wiley
SourceType Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 631
SubjectTerms Adaptor Proteins, Signal Transducing - metabolism
Adenosine Triphosphate - metabolism
Aged
ALS
Amyotrophic lateral sclerosis
Amyotrophic Lateral Sclerosis - blood
Amyotrophic Lateral Sclerosis - pathology
Biomarkers
Case-Control Studies
Chains
Cohort Studies
Computer simulation
Control methods
Disease Progression
energy
Energy conservation
Energy consumption
Energy Metabolism - physiology
Female
Humans
Immunology
In vivo methods and tests
Isoforms
Male
Middle Aged
Monte Carlo simulation
Motor neurons
Motor Neurons - physiology
Motors
Neurodegeneration
Neurofilament Proteins - blood
Neurofilament Proteins - metabolism
neurofilaments
Original
ORIGINAL ARTICLES
Protein Isoforms - blood
Proteins
Stoichiometry
Time Factors
Title A motor neuron strategy to save time and energy in neurodegeneration: adaptive protein stoichiometry
URI https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fjnc.14542
https://www.ncbi.nlm.nih.gov/pubmed/29959860
https://www.proquest.com/docview/2110229338
https://www.proquest.com/docview/2062832561
https://pubmed.ncbi.nlm.nih.gov/PMC6175430
Volume 146
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3La9wwEIeHNJf20kfSh9t0UUspuTisZUleJ6dlaQg5hFIayKFg9HKzpJVDdreQ_vWdkR9kkxRKbwaPbdmekX5jjz4BfNC69uOxGadOSp2SZEgnJvdpXeBgkhlOkpyqLU7U0ak4PpNnG3DQz4Vp-RDDBzeKjNhfU4Brs7gZ5Bg_mZCC-l-q1SJB9GVARxE2KxtI4eiZHVUoVvH0R66PRXcE5t06yZv6NQ5Ah0_gW9_0tu7kYm-1NHv29y2q43_e21N43AlTNm096Rls-LAF29OASfnPa_aRxVLR-A1-Cx7O-mXitsFNGb7t5opFMmZgixZ3e82WDVvoX57R6vVMB8d8nGbI5qE1df57RF6TZ-wz7fQl9bwsgiPmdJ5mbs8JDoCXeQ6nh5--zo7SbumG1AqR89QoizqsVrVGCVIbbXQhPOZ21iluTaldKQhEI0tuC1vWmdLa5LoW3EjsYqTPX8BmaIJ_BcyWWWklF87WueCF1coWBvMsZaUX1roEdvuXWNmOa07La_yohvwm2Co-zQTeD6aXLczjPqOd3hOqLp4XFaXJHJVRPkng3bAbnzT9XtHBNyu0oemo2HiVJfCydZzhKpywbhM1TqBYc6nBgCjf63vC_DzSvlFiSpHjkbvRY_7e8Or4ZBY3Xv-76Rt4hApw0hbN7cDm8mrl36LKWpoRPODi8ygG1YjGO_kHRT8npg
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB5V7aFceLQ8AgUMQqiXVJvEdjaIy2pFtZSyB9RKvaDIr7QrwKm6u5XaX98Z56EuBQlxi-Rx7Ngz9jfO-BuAd0pVbjDQg9gKoWKCDPFQZy6uctxMEp0SJKdoi6mcHPODE3GyBh-7uzANP0R_4EaWEdZrMnA6kL5t5WhACRccF-ANyugdHKpvPXkUEWclPVc46mbLKxTieLqqq7vRHYh5N1LyNoINW9D-A_jedb6JPPmxt1zoPXP9G6_j_37dQ7jfYlM2apTpEaw5vwXbI49--a8r9p6FaNFwDL8Fm-MuU9w22BHDCa8vWCDH9GzeMN5esUXN5urSMUpgz5S3zIWbhmzmG1HrTgPrNSnHB6asOqfFlwXuiBm9p56ZM-IHwGYew_H-p6PxJG6zN8SG8yyNtTQIxSpZKUQhlVZa5dyhe2esTI0ulC04cdGIIjW5KapEKqUzVfFUC1xlhMuewLqvvXsGzBRJYUTKrakynuZGSZNrdLWkEY4bYyPY7WaxNC21OWXY-Fn2Lo43ZRjNCN72oucNn8efhHY6VShbk56X5CmnCI6yYQRv-mIcafrDoryrlyhDN1Kx8zKJ4GmjOX0rKTG7DeUggnxFp3oBIvpeLfGzs0D4jShT8Axr7gaV-XvHy4PpODw8_3fR17A5Ofp6WB5-nn55AfcQEA6bGLodWF9cLN1LBF0L_SrY1g2pyCoE
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnZ3fa9RAEMeHUkF98UerNVp1FZG-pCSb3U2iT8fVo1Y5RCz0QQj7K_aw3Ry9O6H-9c5uftCzCuJbIJNkk8zsfieZ_SzAKylrmyQqiQ3nMvaSIS5UZuM6x8EkVdRLcl9tMRWHx-zohJ9swNt-LkzLhxg-uPnICP21D_C5qa8GOcZPyjjD_vcGE0nhXfrg88CO8tysdECFo2t2WKFQxtMfuj4YXVOY1wslrwrYMAJN7sLXvu1t4cn3_dVS7eufv2Ed__Pm7sGdTpmSUetK92HDui3YHjnMys8vyWsSakXDR_gtuDXu14nbBjMi-LqbCxLQmI4sWt7tJVk2ZCF_WOKXryfSGWLDPEMyc62psd8C89q7xhsijZz7rpcEcsTMn6eZ6VNPB8DLPIDjybsv48O4W7sh1oxlNFZCoxCrRS1Rg9RKKpkzi8mdNoJqVUpTMk-i4SXVuS7rVEipMlkzqjj2MdxmD2HTNc4-AqLLtNScMqPrjNFcS6FzhYmW0NwyrU0Ee_1LrHQHNvfra5xVQ4LjdBWeZgQvB9N5S_P4k9Fu7wlVF9CLyufJFKVRVkTwYtiNT9r_X5HONiu08fNRsfEijWCndZzhKtRz3QqRRJCvudRg4DHf63vc7DTgvlFjcpbhkXvBY_7e8OpoOg4bj__d9Dnc_HQwqT6-n354ArdRDRZtAd0ubC4vVvYpKq6lehYi6xc2-yi8
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+motor+neuron+strategy+to+save+time+and+energy+in+neurodegeneration%3A+adaptive+protein+stoichiometry&rft.jtitle=Journal+of+neurochemistry&rft.au=Zucchi%2C+Elisabetta&rft.au=Lu%2C+Ching%E2%80%90Hua&rft.au=Cho%2C+Yunju&rft.au=Chang%2C+Rakwoo&rft.date=2018-09-01&rft.issn=0022-3042&rft.eissn=1471-4159&rft.volume=146&rft.issue=5&rft.spage=631&rft.epage=641&rft_id=info:doi/10.1111%2Fjnc.14542&rft.externalDBID=10.1111%252Fjnc.14542&rft.externalDocID=JNC14542
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-3042&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-3042&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-3042&client=summon